65 related articles for article (PubMed ID: 38486250)
21. Flavonoid 4,4'-dimethoxychalcone induced ferroptosis in cancer cells by synergistically activating Keap1/Nrf2/HMOX1 pathway and inhibiting FECH.
Yang C; Wang T; Zhao Y; Meng X; Ding W; Wang Q; Liu C; Deng H
Free Radic Biol Med; 2022 Aug; 188():14-23. PubMed ID: 35697292
[TBL] [Abstract][Full Text] [Related]
22. Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy.
Kannan S; Irwin ME; Herbrich SM; Cheng T; Patterson LL; Aitken MJL; Bhalla K; You MJ; Konopleva M; Zweidler-McKay PA; Chandra J
Antioxidants (Basel); 2022 Apr; 11(4):. PubMed ID: 35453402
[TBL] [Abstract][Full Text] [Related]
23. Tumor-derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer.
Shi W; Zhang F; Chen X; Wang S; Zhang H; Yang Z; Wang G; Zheng Y; Han Y; Sun Y; Gao A
Cancer Sci; 2022 Jun; 113(6):1939-1954. PubMed ID: 35377522
[TBL] [Abstract][Full Text] [Related]
24. Association between diminished miRNA expression and the disease status of AML patients: Comparing to healthy control.
Chen DP; Chang SW; Wen YH; Wang WT
Biomed J; 2023 Apr; 46(2):100518. PubMed ID: 35307582
[TBL] [Abstract][Full Text] [Related]
25. Emerging concepts of miRNA therapeutics: from cells to clinic.
Diener C; Keller A; Meese E
Trends Genet; 2022 Jun; 38(6):613-626. PubMed ID: 35303998
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.
Sun R; Zhang PP; Weng XQ; Gao XD; Huang CX; Wang L; Hu XX; Xu PP; Cheng L; Jiang L; Fu D; Qu B; Zhao Y; Feng Y; Dou HJ; Zheng Z; Zhao WL
Signal Transduct Target Ther; 2022 Mar; 7(1):80. PubMed ID: 35301282
[TBL] [Abstract][Full Text] [Related]
27. MiRNA-301b-3p induces proliferation and inhibits apoptosis in AML cells by targeting FOXF2 and regulating Wnt/β-catenin axis.
Lu Y; Zhong L; Luo X; Liu C; Dan W; Chu X; Wan P; Zhang Z; Wang X; Liu Z; Liu B
Mol Cell Probes; 2022 Jun; 63():101805. PubMed ID: 35259424
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting collagen I production and tumor cell colonization in the lung
Yan Y; Du C; Duan X; Yao X; Wan J; Jiang Z; Qin Z; Li W; Pan L; Gu Z; Wang F; Wang M; Qin Z
Acta Pharm Sin B; 2022 Feb; 12(2):939-951. PubMed ID: 35256956
[TBL] [Abstract][Full Text] [Related]
29. LILRB3 as a regulator of AML survival.
Lasry A; Aifantis I
Nat Cancer; 2021 Nov; 2(11):1122-1123. PubMed ID: 35122058
[No Abstract] [Full Text] [Related]
30. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-κB signaling axis.
Wu G; Xu Y; Schultz RD; Chen H; Xie J; Deng M; Liu X; Gui X; John S; Lu Z; Arase H; Zhang N; An Z; Zhang CC
Nat Cancer; 2021 Nov; 2(11):1170-1184. PubMed ID: 35122056
[TBL] [Abstract][Full Text] [Related]
31. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer.
Li L; He D; Guo Q; Zhang Z; Ru D; Wang L; Gong K; Liu F; Duan Y; Li H
J Nanobiotechnology; 2022 Jan; 20(1):50. PubMed ID: 35078498
[TBL] [Abstract][Full Text] [Related]
32. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
33. Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics.
Abdallah F; Coindre S; Gardet M; Meurisse F; Naji A; Suganuma N; Abi-Rached L; Lambotte O; Favier B
Front Immunol; 2021; 12():717998. PubMed ID: 34594332
[TBL] [Abstract][Full Text] [Related]
34. HMOX1 upregulation promotes ferroptosis in diabetic atherosclerosis.
Meng Z; Liang H; Zhao J; Gao J; Liu C; Ma X; Liu J; Liang B; Jiao X; Cao J; Wang Y
Life Sci; 2021 Nov; 284():119935. PubMed ID: 34508760
[TBL] [Abstract][Full Text] [Related]
35. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
Niederkorn M; Ishikawa C; M Hueneman K; Bartram J; Stepanchick E; R Bennett J; E Culver-Cochran A; Bolanos LC; Uible E; Choi K; Wunderlich M; Perentesis JP; M Chlon T; Filippi MD; Starczynowski DT
Leukemia; 2022 Feb; 36(2):438-451. PubMed ID: 34465865
[TBL] [Abstract][Full Text] [Related]
36. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.
Deng M; Chen H; Liu X; Huang R; He Y; Yoo B; Xie J; John S; Zhang N; An Z; Zhang CC
Antib Ther; 2021 Jan; 4(1):16-33. PubMed ID: 33928233
[TBL] [Abstract][Full Text] [Related]
37. Emerging agents and regimens for AML.
Liu H
J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
[TBL] [Abstract][Full Text] [Related]
38. LncRNA LTSCCAT promotes tongue squamous cell carcinoma metastasis via targeting the miR-103a-2-5p/SMYD3/TWIST1 axis.
Liu M; Liu Q; Fan S; Su F; Jiang C; Cai G; Wang Y; Liao G; Lei X; Chen W; Bi J; Cheng W; Zhao L; Ruan Y; Li J
Cell Death Dis; 2021 Feb; 12(2):144. PubMed ID: 33542221
[TBL] [Abstract][Full Text] [Related]
39. Hmox1 (Heme Oxygenase-1) Protects Against Ischemia-Mediated Injury via Stabilization of HIF-1α (Hypoxia-Inducible Factor-1α).
Dunn LL; Kong SMY; Tumanov S; Chen W; Cantley J; Ayer A; Maghzal GJ; Midwinter RG; Chan KH; Ng MKC; Stocker R
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):317-330. PubMed ID: 33207934
[TBL] [Abstract][Full Text] [Related]
40. LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Yeboah M; Papagregoriou C; Jones DC; Chan HTC; Hu G; McPartlan JS; Schiött T; Mattson U; Mockridge CI; Tornberg UC; Hambe B; Ljungars A; Mattsson M; Tews I; Glennie MJ; Thirdborough SM; Trowsdale J; Frendeus B; Chen J; Cragg MS; Roghanian A
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32870822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
